Evidence map›Paper›PMID 39033275›Full record

ArticleVirology journal2024

Resistance to protease inhibitors among persons living with HIV in Ghana: a case for viral load and drug resistance monitoring.

Makafui Seshie, Billal Musah Obeng, Vivian Etsiapa Boamah, Marcel Bayor, Evelyn Yayra Bonney, Stephen Yao Gbedema, Kwamena William Coleman Sagoe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Makafui Seshie *Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana. amaseshie@gmail.com.
Billal Musah Obeng *Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana. vifredobeng@gmail.com.
Vivian Etsiapa BoamahDepartment of Pharmaceutics, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Marcel BayorDepartment of Pharmaceutics, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Evelyn Yayra BonneyDepartment of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Stephen Yao GbedemaDepartment of Pharmaceutics, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Kwamena William Coleman SagoeDepartment of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRoutine viral load and drug resistance testing are well supported in most resource-rich settings and provide valuable benefits in the clinical care of PLWH in these communities. Undoubtedly, there exist financial and political constraints for the scale-up of viral load and drug resistance testing in Sub-Saharan Africa. To achieve the global UNAIDS 95/95/95 targets, there is the need to bridge this inequity in patient care and allow for a universal approach that leaves no community behind.

methodsVenous blood from 96 PLWH on second-line ART from Korle-Bu Teaching Hospital were collected and processed into plasma for CD4

resultsOut of the 96 PLWH, 37 experienced virological failure with 8 patients' samples successfully sequenced. The predominant HIV-1 subtype identified was CRF02_AG (6/8, 75.0%) with 12.5% (1/8) each of CFR06_cpx infection and one case unable to subtype. The major PI resistance mutations identified were; M46I, I54V, V82A, I47V, I84V and L90M.

conclusionsPersons living with HIV who had experienced virologic failure in this study harboured drug resistance mutations to PI, thus compromise the effectiveness of the drugs in the second line. Resistance testing is strongly recommended prior to switching to a new regimen. This will help to inform the choice of drug and to achieve optimum therapeutic outcome among PLWH in Ghana.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsHIV Protease InhibitorsViral LoadAdultFemaleGenotypeGhanaHIV ProteaseHumansMaleMiddle AgedRNA, ViralSequence Analysis, DNAYoung AdultHIV ProteaseHIV Protease InhibitorsRNA, ViralHIV-1 drug resistance testHIV-1 viral loadHIV care continuumProtease inhibitorsSecond-line ARTTreatment failure

Identifiers

PMID39033275
PMCPMC11265000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.